Amylin Analog Deal Benchmarks in Metabolic & Obesity

Median Upfront

$996M

Range: $547M - $1.4B

Total Deal Value

$4.7B

Range: $3.1B - $6.4B

Royalty Rate

16.3% - 29.9%

Tiered up to 33.9%

Dev Milestones

$670M

Range: $454M - $890M

Model Your Deal

Market Analysis

Amylin Analog therapies in metabolic & obesity have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 amylin analog asset in metabolic & obesity is $996M, with total deal values reaching $4.7B. Development milestones average $670M, while regulatory milestones contribute $819M.

The metabolic & obesity amylin analog landscape is characterized by extremely high competitive intensity driven by the GLP-1 revolution and massive obesity market opportunity. Oral formulations, dual/triple incretins, and muscle-sparing approaches command unprecedented deal valuations. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for amylin analog metabolic & obesity deals range from 16.3% to 29.9% at the base tier, with tiered escalation reaching 20.3%-33.9% on blockbuster sales. Commercial milestones averaging $2.2B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a amylin analog metabolic & obesity licensing deal?

Based on our analysis, Phase 2 amylin analog licensing deals in metabolic & obesity average $996M in upfront payments, with a range of $547M to $1.4B depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for amylin analog metabolic & obesity transactions?

The median total deal value for Phase 2 amylin analog assets in metabolic & obesity is $4.7B, ranging from $3.1B to $6.4B. This includes development milestones ($670M), regulatory milestones ($819M), and commercial milestones ($2.2B).

What royalty rates are standard for amylin analog deals in metabolic & obesity?

Base royalty rates for amylin analog metabolic & obesity transactions range from 16.3% to 29.9%, with tiered escalations reaching 20.3%-33.9% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in amylin analog metabolic & obesity deals?

Amylin Analog metabolic & obesity deals allocate approximately 79% of total deal value to milestones. Development milestones ($670M) make up the largest share, followed by commercial milestones ($2.2B) and regulatory milestones ($819M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

Small Molecule in Metabolic & Obesity

View

GLP-1 Agonist in Metabolic & Obesity

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating